CareDx Inc (CDNA)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.09B
Last updated: Nov 17, 2026 at 11:04 AM ET
CareDx Inc (CDNA) Stock Forecast
Analysts expect CareDx (CDNA) to earn $1.78 per share in the fiscal year ending Dec 31, 2026, on revenue of $524.82M. Of 7 analysts, 5 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.29, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 71% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 71.4% |
| Hold | 2 | 28.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 12.4% and revenue estimates rise 9.0%.
- Fiscal year ending Dec 31, 2026
- $1.78
- EPS consensus, revenue $524.82M
- Fiscal year ending Dec 31, 2027
- $1.56
- EPS consensus, revenue $571.96M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.78 | $1.73 to $1.83 | 7 | $524.82M | $524.40M to $525.20M | 8 |
| Dec 31, 2027 | $1.56 | $1.26 to $1.91 | 7 | $571.96M | $563.50M to $590.00M | 8 |
Quarterly Estimates
The EPS consensus falls from $0.37 for the quarter ending Dec 31, 2026 to $0.31 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.37 | $0.30 to $0.43 | 10 | $135.45M | $109.47M to $143.07M | 10 |
| Mar 31, 2027 | $0.31 | $0.24 to $0.37 | 7 | $130.93M | $127.80M to $133.68M | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 47.1% from $1.21.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.78 | $1.78 | $1.20 | $1.20 | $1.21 | +46.6% |
| Fiscal year ending Dec 31, 2027 | $1.56 | $1.58 | $1.29 | $1.33 | $1.36 | +15.4% |
| Quarter ending Mar 31, 2027 | $0.31 | $0.30 | $0.25 | $0.27 | $0.30 | +2.2% |
Frequently Asked Questions About CDNA
What is the CDNA stock forecast?
Consensus analyst estimates put CareDx's EPS at $1.78 for the fiscal year ending Dec 31, 2026, on revenue of $524.82M. The consensus rating from 7 analysts is Buy.
How do analysts rate CDNA stock?
Of 7 analysts covering CareDx, 0 rate it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CDNA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.78, with estimates from $1.73 to $1.83 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.56, with estimates from $1.26 to $1.91 from 7 analysts.
What revenue do analysts expect from CareDx next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $524.82M, with estimates from $524.40M to $525.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $571.96M, with estimates from $563.50M to $590.00M.
How many analysts cover CDNA?
7 analysts rate CareDx stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CDNA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts